It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AstraZeneca shareholders approve Alexion acquisition

Tue 11 May 2021 13:59 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - AstraZeneca's acquisition of Alexion Pharmaceuticals is set to close in the third quarter after shareholders voted in favour of the deal.

Chief executive Pascal Soriot said: "The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion's leadership in complement biology and rare diseases with AstraZeneca's expertise in precision medicine and growing presence in immunology.

"We look forward to together advancing life-changing science and bringing even more medicines to patients globally."

The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast